Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06853925 · ClinicalTrials.gov registry record · NA
Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
A NA study of Thyroid Neoplasms, sponsored by Georgetown University.
- Recruiting
- Registry status
- NA
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT06853925: Recruiting NA study of Thyroid Neoplasms, sponsored by Georgetown University.
NCT06853925 is a NA study of Thyroid Neoplasms that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 88 participants, below the 827-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06853925, a NA study of Thyroid Neoplasms, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (RAI) treatment. The main questions it aims to answer are: 1. Can patients easily use and benefit from the RAI Support intervention? 2. Does RAI Support improve health-related quality of life (overall well-being) compared to usual care? This research will help test better digital tools to support thyroid cancer survivors in managing their health after RAI treatment. Researchers will compare RAI Support to treatment as usual (a publicly available informational website about thyroid cancer) to see if RAI Support works to improve patients' overall well-being. Participants will: 1. Receive access to RAI Support or an informational website (treatment as usual) for four weeks. 2. Use the assigned website once a week for up to four weeks. 3. Complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to RAI treatment, mood, and confidence in managing symptoms. 4. Complete an optional 60 minute virtual interview about your experiencing using the assigned website.
Primary Outcome
Feasibility is defined by at least 86% of patients are retained and complete the 4-week post-assessment. Feasibility is also defined as greater or equal to 70% RAI Support engagement rate (greater or equal to 3/4 website sections).
Conditions Studied
Interventions
- BEHAVIORAL Radioactive Iodine Support (RAI Support)
- OTHER Treatment as Usual (TAU)
Study Locations (1)
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2027-02 |
| Phase | NA |
What NCT06853925 shows while recruiting
NCT06853925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 827-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Thyroid Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Radioactive Iodine Support (RAI Support) is the first listed.
NCT06853925 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06853925 about?
NCT06853925 is a clinical study titled "Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients". The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (...
What is the current status of trial NCT06853925?
This trial is currently recruiting. It is a NA study. The enrollment target is 88 participants. The study started on 2025-10-02. Estimated completion is 2027-02.
What conditions does trial NCT06853925 study?
This clinical trial studies the following conditions: Thyroid Neoplasms.
What interventions are being tested in trial NCT06853925?
The interventions under investigation include: Radioactive Iodine Support (RAI Support) (BEHAVIORAL), Treatment as Usual (TAU) (OTHER).
Who is sponsoring clinical trial NCT06853925?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06853925 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAIL Study: Feasibility and Pilot
RECRUITING · NA
-
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
RECRUITING
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 1
-
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
COMPLETED · Phase 3
-
Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI